Methotrexate, Serum
Methotrexate (MTX) is a folate antagonist widely used in oncology, autoimmune disease management, and ectopic pregnancy therapy. It competitively inhibits dihydrofolate reductase (DHFR), an enzyme essential for tetrahydrofolate (THF) synthesis. THF is a critical cofactor for purine and thymidylate biosynthesis, which are required for DNA and RNA synthesis. DHFR Inhibition disrupts DNA replication and repair, leading to apoptosis of rapidly dividing cancer cells.
In addition to its anti-proliferative effect, methotrexate increases extracellular adenosine, a potent anti-inflammatory mediator, which explains its use in autoimmune conditions such as rheumatoid arthritis, psoriasis, and systemic lupus erythematosus. In obstetrics, MTX is used as a medical alternative to surgery in the management of ectopic pregnancy. Despite its clinical utility, methotrexate has a narrow therapeutic window. Toxic levels may cause myelosuppression with pancytopenia and increased infection risk, hepatotoxicity leading to fibrosis and cirrhosis with chronic use, gastrointestinal mucosal injury with mucositis and enteritis, nephrotoxicity due to intratubular crystal precipitation and acute kidney injury, pulmonary toxicity manifesting as interstitial pneumonitis, and hypersensitivity reactions. Monitoring serum methotrexate concentrations is therefore critical, especially in patients receiving high-dose chemotherapy regimens, to avoid toxicity. In such settings, leucovorin (folinic acid) rescue is used to counteract the harmful effects of methotrexate.
- Monitor serum methotrexate levels in oncology patients receiving high-dose therapy to avoid any toxicity and side effects
- Ensure therapeutic but safe drug exposure in autoimmune disease management
Nontoxic drug concentration after 72 hours: <0.1 mcmol/L
Serum, SST tube.
Stability
- Ambient: 72 hrs.
- Refrigerated: 7-14 days
- Frozen: 28 days
- Biochem Soc Trans. 2020 Apr 29;48(2):559-567. [PMID: 32239204]
- Cureus. 2022 Sep 23;14(9):e29518. [PMID: 36312688]
- N Engl J Med. 1983;309(18):1094–1104. [PMID: 6353235]
- Oncologist. 2016 Dec;21(12):1471-1482. [PMID: 27496039]
- Rheumatology (Oxford). 2004 Mar;43(3):267-71. [PMID: 14963199]
- Br J Clin Pharmacol. 2025 Mar;91(3):628-635. [PMID: 38889902]